University of Wisconsin Foundation Sells 13,219 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

University of Wisconsin Foundation lowered its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 410,630 shares of the company's stock after selling 13,219 shares during the quarter. Akero Therapeutics makes up about 8.3% of University of Wisconsin Foundation's holdings, making the stock its 6th largest holding. University of Wisconsin Foundation owned 0.59% of Akero Therapeutics worth $11,424,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sterling Capital Management LLC boosted its holdings in shares of Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares during the last quarter. AlphaQuest LLC boosted its stake in Akero Therapeutics by 32,588.0% during the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after buying an additional 8,147 shares during the last quarter. Optimize Financial Inc purchased a new stake in Akero Therapeutics in the 4th quarter valued at $232,000. Sei Investments Co. acquired a new stake in shares of Akero Therapeutics in the 4th quarter worth $303,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Akero Therapeutics in the 4th quarter worth $306,000.

Akero Therapeutics Stock Performance

Akero Therapeutics stock traded down $0.64 during mid-day trading on Wednesday, reaching $37.44. The company's stock had a trading volume of 498,122 shares, compared to its average volume of 855,912. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The business has a 50 day moving average price of $44.12 and a 200-day moving average price of $35.99. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -9.98 and a beta of -0.18.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AKRO shares. Canaccord Genuity Group upped their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright upped their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Finally, Citigroup upped their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $76.29.

Insider Buying and Selling at Akero Therapeutics

In related news, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $54.90, for a total value of $1,647,000.00. Following the completion of the transaction, the chief executive officer now owns 716,062 shares in the company, valued at $39,311,803.80. This represents a 4.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Timothy Rolph sold 31,250 shares of the business's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $55.77, for a total transaction of $1,742,812.50. Following the sale, the insider now owns 170,237 shares in the company, valued at $9,494,117.49. This trade represents a 15.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 341,309 shares of company stock worth $15,863,578 and have sold 287,458 shares worth $13,689,886. 7.94% of the stock is owned by company insiders.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.